| [1] |
. Nanomedicine （Lond），2015，10（1）：161-174.
|
| [2] |
Revets H，De Baetselier P，Muyldermans S. Nanobodies as novel agents for cancer therapy［J］. Expert Opin Biol Ther，2005，5（1）：111-124.
|
| [3] |
Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases：current state and prospects［J］. Drug Discov Today，2018，23（12）：1996-2002.
|
| [4] |
Roovers RC，Vosjan MJ，Laeremans T，et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth［J］. Int J Cancer，2011，129（8）：2013-2024.
|
| [5] |
Peyvandi F，Scully M，Kremer Hovinga JA，et al. Caplacizumab for acquired thrombotic thrombocytopenic Purpura［J］. N Engl J Med，2016，374（6）：511-522.
|
| [6] |
Xing XY，Wang XC，He W. Advances in research on tumor immunotherapy and its drug development［J］. J China Pharm Univ（中国药科大学学报），2021，52（1）：10-19.
|
| [7] |
Yang J，Hu LQ. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction：from antibodies to small molecules［J］. Med Res Rev，2019，39（1）：265-301.
|
| [8] |
Asano T，Meguri Y，Yoshioka T，et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy［J］. Blood，2017，129（15）：2186-2197.
|
| [9] |
Zou W，Wolchok JD，Chen L. PD-L1 （B7-H1） and PD-1 pathway blockade for cancer therapy：mechanisms，response biomarkers，and combinations［J］. Sci Transl Med，2016，8（328）：328rv4.
|
| [10] |
Nowicki TS，Hu-Lieskovan S，Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade［J］. Cancer J，2018，24（1）：47-53.
|
| [11] |
Anderson KG，Stromnes IM，Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity：a case for synergistic therapies［J］. Cancer Cell，2017，31（3）：311-325.
|
| [12] |
Domanska UM，Kruizinga RC，Nagengast WB，et al. A review on CXCR4/CXCL12 axis in oncology：no place to hide［J］. Eur J Cancer，2013，49（1）：219-230.
|
| [13] |
Scala S. Molecular pathways：targeting the CXCR4-CXCL12 axis：untapped potential in the tumor microenvironment［J］. Clin Cancer Res，2015，21（19）：4278-4285.
|
| [14] |
Bockorny B，Semenisty V，Macarulla T，et al. BL-8040，a CXCR4 antagonist，in combination with pembrolizumab and chemotherapy for pancreatic cancer：the COMBAT trial［J］. Nat Med，2020，26（6）：878-885.
|
| [15] |
Abraham M，Mishalian I，Harel Y，et al. Effect of BL-8040，high-affinity CXCR4 antagonist，on T-cell infiltration，tumor growth，and synergy with immunomodulatory agents［J］. J Clin Oncol，2017，35（15_suppl）：e14544.
|
| [16] |
Li ZT，Wang YX，Shen YX，et al. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy［J］. Sci Adv，2020，6（20）：eaaz9240.
|
| [17] |
Zhang F，Wei HD，Wang XX，et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade［J］. Cell Discov，2017，3：17004.
|
| [18] |
J?hnichen S，Blanchetot C，Maussang D，et al. CXCR4 nanobodies （VHH-based single variable domains） potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells［J］. PNAS，2010，107（47）：20565-20570.
|
| [19] |
Yang WH，Chen PW，Li HC，et al. PD-L1：PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro［J］. Invest Ophthalmol Vis Sci，2008，49（6）：2518-2525.
|
| [20] |
Suurs FV，Lub-de Hooge MN，de Vries EGE，et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges［J］. Pharmacol Ther，2019，201：103-119.
|
| [21] |
Qin WT，Hu LP，Zhang XL，et al. The diverse function of PD-1/PD-L pathway beyond cancer［J］. Front Immunol，2019，10：2298.
|
| [22] |
Seo YD，Jiang XY，Sullivan KM，et al. Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer［J］. Clin Cancer Res，2019，25（13）：3934-3945.
|
| [23] |
Decrop W，Swart R，Gendeh G. Development of an automated method for monoclonal antibodies purification and analysis［J］. J Biomol Tech，2010，21（3 suppl）：S34-S35.
|
百度学术
下载:
